NEW YORK (GenomeWeb) – Transgenomic today said that its common shares have been approved for uplisting to the Nasdaq Capital Market.
Its shares, which are currently listed on the OTC Bulletin Board under ticker symbol "TBIO," will start trading on the Nasdaq on May 9 under the same ticker symbol.
"We believe that trading on the Nasdaq market will expand our visibility and provide us access to a broader investor base, helping us translate our strategic growth initiatives and renewed focus on implementation into increased shareholder value going forward," Transgenomic President and CEO Paul Kinnon said in a statement.
The company filed with Nasdaq in January to have its shares listed on the exchange.